Valneva Stock Forecast
NASDAQ: VALNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
VALN analyst consensus
Consensus (4 analysts)
buy
Avg. price target
$12.25+115.29%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering Valneva (2026-10-08), 3 rate the stock a buy or strong buy, 0 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $12.25, with a high estimate of $18.00 and a low estimate of $5.00. The average target implies upside of 115.3% from the current price of $5.69.
The spread between the highest and lowest targets is 260.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for VALN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 75% |
| Hold | 0 | 0% |
| Sell | 1 | 25% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $5.00 | -12.13% |
| Average target | $12.25 | +115.29% |
| High target | $18.00 | +216.34% |